#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Retinal dystrophy Arginase deficiency Growth hormone deficiency Ocular myasthenia Acquired C1 inhibitor deficiency Cutaneous calcification Acute myeloid leukaemia recurrent Hereditary neuropathic amyloidosis Thrombotic thrombocytopenic purpura Hypergammaglobulinaemia benign monoclonal Anti-myelin-associated glycoprotein associated polyneuropathy T-cell lymphoma Acute lymphocytic leukaemia Marfan's syndrome Ventricular tachycardia More trials…

    Learn about Rare Diseases

    Burkitt’s lymphoma – Diagnostics Pulmonary fibrosis – Trials in Disease Malignant fibrous histiocytoma – Life with Disease Pituitary-dependent Cushing’s syndrome – Trials in Disease Pulmonary sarcoidosis – Diagnostics Sarcoma – Diagnostics Angelman’s syndrome – Basic Information Primary mediastinal large B-cell lymphoma – Trials in Disease IgA nephropathy – Treatment Richter’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Wt1/Il15/Il15Ra Mrna Dc Mk-0482 Dazucorilant Tpst-1120 Cholesterol DISODIUM PHOSPHATE Mr0005 M1P Dipotassium Salt Pralatrexate Bleomycin Sulfate Ph. Eur. Mps-112 Rotigotine ALE.P03 Dolutegravir Ipatasertib VMX-C001 Frexalimab Enpatoran Germanium (68Ge) Chloride Tofacitinib Citrate More therapies…

    Learn about Your Condition

    Head and neck cancer Merycism Aphthous ulcer Hypomagnesaemia Ehlers-Danlos syndrome Breast conserving surgery Systemic infection Kawasaki's disease Pelizaeus-Merzbacher disease Krabbe's disease Meningorrhagia Neuropathic arthropathy Huntington's disease Antisynthetase syndrome Rheumatoid arthritis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hypertrophic cardiomyopathy

  • Comparing hydrochlorothiazide and valsartan for treating high blood pressure in patients with hypertrophic obstructive cardiomyopathy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hypertrophic cardiomyopathy
    Investigated Drugs:
    • Hydrochlorothiazide
    • Valsartan
    Austria

  • A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

    Recruiting

    2 1
    Investigated Diseases:
    • Cardiomyopathy
    • Hypertrophic cardiomyopathy
    Austria Belgium France Germany Italy The Netherlands +3

  • Study Evaluating Direct Oral Anticoagulants for Prevention of Blood Clots in Patients with Hypertrophic Cardiomyopathy and Abnormal Left Atrial Function

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hypertrophic cardiomyopathy
    Investigated Drugs:
    • Rivaroxaban
    France

  • Study on Sotagliflozin for Improving Symptoms in Patients with Hypertrophic Cardiomyopathy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hypertrophic cardiomyopathy
    Investigated Drugs:
    • Sotagliflozin
    Belgium Bulgaria Croatia Czechia France Germany +7

  • Study of Aficamten for Children with Symptomatic Obstructive Hypertrophic Cardiomyopathy

    Recruiting

    4 1
    Investigated Diseases:
    • Hypertrophic cardiomyopathy
    Investigated Drugs:
    • Aficamten
    Ireland Italy Spain

  • Study on the Long-Term Safety of Aficamten (CK-3773274) for Patients with Symptomatic Hypertrophic Cardiomyopathy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hypertrophic cardiomyopathy
    Investigated Drugs:
    • Aficamten
    Czechia Denmark France Germany Greece Hungary +6
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!